Phase II trials for cocaine addiction drug 'hits enrolment target'

Categories

Addiction Treatment
Alcohol
Drugs
Gambling
In the papers
On TV

News Archive

Home » News » Drugs » Phase II trials for cocaine addiction drug 'hits enrolment target'

by Change | 13 Jan 2009

Bookmark

E-mail

Enrolment targets for the next phase of trials for the CPP-109 treatment have been met, meaning it could soon be appearing in rehab clinics.

The patient enrolment target for the next stage of clinical testing of a cocaine addiction drug has been reached.

Phase two trials for CPP-109, a formulation including vigabatrin which is expected to be capable of treating methamphetamine and cocaine dependencies, will now be able to go ahead.

Developed by Catalyst Pharmaceutical Partners, the medicine could play a part in addiction rehabilitation clinics and be used to treat other forms of mental illness, such as obsessive-compulsive disorders.

The test will be randomised, compared with a control study involving placebos and to assess the safety of the drug, as well as its efficacy over a 12-week treatment period, as is often used in treatment centres.

Dr Eugene Somoza, director of Cincinnati's Addiction Research Centre and the coordinating principal investigator, claims meeting the trial's enrolment targets is an "outstanding accomplishment for the addiction field".

He states: "An effective medication for treating cocaine addiction has been eagerly awaited for a long time by numerous individuals, families and treatment providers and this milestone brings us one step closer to the goal."

Last year, clinical trial results published in the Journal of the American Medical Association found suboxone could have a use in rehab clinics as a method of reducing addiction relapse.

Bookmark this: